Shorter treatment for TB with diabetes and drug resistance
Part of Hormones & metabolism clinical trials.
This trial tests a shorter treatment regimen for people who have both diabetes and a type of tuberculosis (TB) that is resistant to the usual medicines. The goal is to see if the new treatment works well and is safe for this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older and weigh at least 66 pounds (30 kg).
- You have active lung TB that is resistant to at least rifampin (one of the main TB drugs).
- You have been diagnosed with diabetes (type 1 or type 2).
- Women who can become pregnant must have a negative pregnancy test and use effective birth control during the study plus 3 months after. Men must use condoms or other effective contraception for their partners.
- You must agree to an HIV test; if positive, you will take HIV medicines.
- You have not already taken bedaquiline or delamanid (other TB drugs) for more than 28 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
This trial tests a shorter treatment for drug-resistant tuberculosis (TB) using the medicine Pretomanid. It aims to find a more manageable cure for people whose TB does not respond to the standard first-line drug, rifampicin.
This trial tests a shorter course of three drugs (bedaquiline, moxifloxacin, and pyrazinamide) for people with newly diagnosed, drug-sensitive TB. It aims to see how quickly the drugs kill the bacteria in the first few days of treatment.
This trial tests a shorter treatment for TB that is resistant to the drug rifampicin but still sensitive to isoniazid. It may help people finish treatment sooner and with fewer side effects.
This trial tests a three-drug combination (bedaquiline, delamanid, and linezolid) to see if it's safe and works well for people with multi-drug resistant or rifampicin-resistant tuberculosis. It may offer a new treatment option if standard drugs aren't working.
This trial studies a specific drug combination (BPaLM) for adults with drug-resistant pulmonary (lung) tuberculosis. If you qualify, the goal is to see whether this treatment is effective and safe for your type of infection.
Hear when a new Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.